The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin
- PMID: 11709539
- DOI: 10.1093/hmg/10.22.2515
The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin
Abstract
Huntingtin is an essential protein that with mutant polyglutamine tracts initiates dominant striatal neurodegeneration in Huntington's disease (HD). To assess the consequences of mutant protein when huntingtin is limiting, we have studied three lines of compound heterozygous mice in which both copies of the HD gene homolog (Hdh) were altered, resulting in greatly reduced levels of huntingtin with a normal human polyglutamine length (Q20) and/or an expanded disease-associated segment (Q111): Hdh(neoQ20)/Hdh(neoQ20), Hdh(neoQ20)/Hdh(null) and Hdh(neoQ20)/Hdh(neoQ111). All surviving mice in each of the three lines were small from birth, and had variable movement abnormalities. Magnetic resonance micro-imaging and histological evaluation showed enlarged ventricles in approximately 50% of the Hdh(neoQ20)/Hdh(neoQ111) and Hdh(neoQ20)/Hdh(null) mice, revealing a developmental defect that does not worsen with age. Only Hdh(neoQ20)/Hdh(neoQ111) mice exhibited a rapidly progressive movement disorder that, in the absence of striatal pathology, begins with hind-limb clasping during tail suspension and tail stiffness during walking by 3-4 months of age, and then progresses to paralysis of the limbs and tail, hypokinesis and premature death, usually by 12 months of age. Thus, dramatically reduced huntingtin levels fail to support normal development in mice, resulting in reduced body size, movement abnormalities and a variable increase in ventricle volume. On this sensitized background, mutant huntingtin causes a rapid neurological disease, distinct from the HD-pathogenic process. These results raise the possibility that therapeutic elimination of huntingtin in HD patients could lead to unintended neurological, as well as developmental side-effects.
Similar articles
-
Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum.Hum Mol Genet. 2003 Feb 1;12(3):273-81. doi: 10.1093/hmg/ddg056. Hum Mol Genet. 2003. PMID: 12554681
-
Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.Hum Mol Genet. 2006 Jun 15;15(12):2015-24. doi: 10.1093/hmg/ddl125. Epub 2006 May 10. Hum Mol Genet. 2006. PMID: 16687439
-
Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.Hum Mol Genet. 2011 Jun 15;20(12):2344-55. doi: 10.1093/hmg/ddr127. Epub 2011 Mar 29. Hum Mol Genet. 2011. PMID: 21447599 Free PMC article.
-
Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.J Neurochem. 2010 Jul;114(1):1-12. doi: 10.1111/j.1471-4159.2010.06741.x. Epub 2010 Apr 9. J Neurochem. 2010. PMID: 20403078 Review.
-
Altered microRNA expression in animal models of Huntington's disease and potential therapeutic strategies.Neural Regen Res. 2021 Nov;16(11):2159-2169. doi: 10.4103/1673-5374.310673. Neural Regen Res. 2021. PMID: 33818488 Free PMC article. Review.
Cited by
-
Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.Prog Neurobiol. 2012 May;97(2):190-204. doi: 10.1016/j.pneurobio.2011.11.004. Epub 2011 Nov 18. Prog Neurobiol. 2012. PMID: 22120646 Free PMC article. Review.
-
Nucleic Acid-Based Therapy Approaches for Huntington's Disease.Neurol Res Int. 2012;2012:358370. doi: 10.1155/2012/358370. Epub 2012 Jan 11. Neurol Res Int. 2012. PMID: 22288011 Free PMC article.
-
VGF and striatal cell damage in in vitro and in vivo models of Huntington's disease.Pharmacol Res Perspect. 2015 Jun;3(3):e00140. doi: 10.1002/prp2.140. Epub 2015 May 4. Pharmacol Res Perspect. 2015. PMID: 26171223 Free PMC article.
-
Magnetic Resonance Imaging to Detect Structural Brain Changes in Huntington's Disease: A Review of Data from Mouse Models.J Huntingtons Dis. 2024;13(3):279-299. doi: 10.3233/JHD-240045. J Huntingtons Dis. 2024. PMID: 39213087 Free PMC article. Review.
-
Multiple discrete soluble aggregates influence polyglutamine toxicity in a Huntington's disease model system.Sci Rep. 2016 Oct 10;6:34916. doi: 10.1038/srep34916. Sci Rep. 2016. PMID: 27721444 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases